Matching articles for "rhinosinusitis"
In Brief: Dupilumab (Dupixent) for Allergic Fungal Rhinosinusitis
Dupilumab ( Dupixent – Sanofi/Regeneron), a subcutaneously injected interleukin (IL)-4 receptor alpha antagonist that is FDA-approved for several indications, including treatment of chronic rhinosinusitis…
Med Lett Drugs Ther. 2026 Jun 22; 68(1757):102-3 doi:10.58347/tml.2026.1757e
Dupilumab ( Dupixent – Sanofi/Regeneron), a subcutaneously injected interleukin (IL)-4 receptor alpha antagonist that is FDA-approved for several indications, including treatment of chronic rhinosinusitis with nasal polyps, has now been approved for treatment of allergic fungal rhinosinusitis (AFRS) in patients ≥6 years old who previously had sinonasal surgery. It is the first drug to be approved in the US for this indication.
